Purchase price of US$73 per share in cash represents an enterprise value of US$11.3 billion (EUR 9.9 billion) Proposed acquisition expected to be immediately...
Merck KGaA is set to acquire Bio-Techne for US$73 per share, a deal valued at an enterprise value of US$11.3 billion (EUR 9.9 billion). This strategic acquisition aims to significantly strengthen Merck's leadership in the fast-growing life sciences markets. The proposed…
Market Samachar is a news aggregator. This article was originally published by PRNewswire. Tap the button above to read the full story on their site.